Thanh Bach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2961161/publications.pdf

Version: 2024-02-01

1306789 1372195 12 116 7 10 citations h-index g-index papers 12 12 12 146 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	29
2	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	17
3	Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	14
4	Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 171, 111-117.	1.4	14
5	Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
6	General Pharmacokinetic Features of Smallâ€Molecule Compounds Exhibiting Targetâ€Mediated Drug Disposition (TMDD): A Simulationâ€Based Study. Journal of Clinical Pharmacology, 2019, 59, 394-405.	1.0	9
7	Aspects of matrix and analyte effects in clinical pharmacokinetic sample analyses using LC-ESI/MS/MS – Two case examples. Journal of Pharmaceutical and Biomedical Analysis, 2020, 183, 113135.	1.4	7
8	Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2022, 210, 114521.	1.4	7
9	Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	5
10	Importance of Utilizing Natural Isotopologue Transitions in Expanding the Linear Dynamic Range of LC-MS/MS Assay for Small-Molecule Pharmacokinetic Sample Analysis – A Mini-review. Journal of Pharmaceutical Sciences, 2022, 111, 1245-1249.	1.6	3
11	Comparing the performance of first-order conditional estimation (FOCE) and different expectation–maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 581-595.	0.8	0
12	Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0143221.	1.4	0